IL241473B - N-acyl-6, 5-dihydro-[1,2,4]triazolo[-4,3]pyrazines converted at positions 3 and 8 as selective antagonists of the 3-nk receptor, pharmaceutical preparations containing them, and their uses in the treatment and prevention of Dysfunction of the 3– nk receptor - Google Patents

N-acyl-6, 5-dihydro-[1,2,4]triazolo[-4,3]pyrazines converted at positions 3 and 8 as selective antagonists of the 3-nk receptor, pharmaceutical preparations containing them, and their uses in the treatment and prevention of Dysfunction of the 3– nk receptor

Info

Publication number
IL241473B
IL241473B IL241473A IL24147315A IL241473B IL 241473 B IL241473 B IL 241473B IL 241473 A IL241473 A IL 241473A IL 24147315 A IL24147315 A IL 24147315A IL 241473 B IL241473 B IL 241473B
Authority
IL
Israel
Prior art keywords
substituted
receptor
pyrazines
triazolo
dihydro
Prior art date
Application number
IL241473A
Other languages
English (en)
Hebrew (he)
Other versions
IL241473A0 (en
Inventor
Hoveyda Hamid
Dutheuil Guillaume
Fraser Graeme
Original Assignee
Ogeda Sa
Hoveyda Hamid
Dutheuil Guillaume
Fraser Graeme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ogeda Sa, Hoveyda Hamid, Dutheuil Guillaume, Fraser Graeme filed Critical Ogeda Sa
Publication of IL241473A0 publication Critical patent/IL241473A0/en
Publication of IL241473B publication Critical patent/IL241473B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL241473A 2013-03-29 2015-09-10 N-acyl-6, 5-dihydro-[1,2,4]triazolo[-4,3]pyrazines converted at positions 3 and 8 as selective antagonists of the 3-nk receptor, pharmaceutical preparations containing them, and their uses in the treatment and prevention of Dysfunction of the 3– nk receptor IL241473B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13161863 2013-03-29
EP13193025 2013-11-15
EP14154303 2014-02-07
PCT/EP2014/056367 WO2014154895A1 (en) 2013-03-29 2014-03-28 NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS

Publications (2)

Publication Number Publication Date
IL241473A0 IL241473A0 (en) 2015-11-30
IL241473B true IL241473B (en) 2019-03-31

Family

ID=50391185

Family Applications (1)

Application Number Title Priority Date Filing Date
IL241473A IL241473B (en) 2013-03-29 2015-09-10 N-acyl-6, 5-dihydro-[1,2,4]triazolo[-4,3]pyrazines converted at positions 3 and 8 as selective antagonists of the 3-nk receptor, pharmaceutical preparations containing them, and their uses in the treatment and prevention of Dysfunction of the 3– nk receptor

Country Status (31)

Country Link
US (3) US9422299B2 (OSRAM)
EP (2) EP3219715A1 (OSRAM)
JP (2) JP6316932B2 (OSRAM)
KR (2) KR102218621B1 (OSRAM)
CN (1) CN105229008B (OSRAM)
AU (1) AU2014242906B2 (OSRAM)
BR (1) BR112015024907B1 (OSRAM)
CA (1) CA2907809C (OSRAM)
CY (2) CY1119576T1 (OSRAM)
DK (1) DK2948455T5 (OSRAM)
EA (1) EA027570B1 (OSRAM)
ES (1) ES2646488T3 (OSRAM)
FI (1) FIC20240019I1 (OSRAM)
FR (1) FR24C1020I1 (OSRAM)
HK (1) HK1244273A1 (OSRAM)
HR (1) HRP20171688T1 (OSRAM)
HU (2) HUE035870T2 (OSRAM)
IL (1) IL241473B (OSRAM)
LT (2) LT2948455T (OSRAM)
MX (1) MX370000B (OSRAM)
NL (1) NL301272I2 (OSRAM)
NO (1) NO2948455T3 (OSRAM)
NZ (1) NZ712802A (OSRAM)
PL (1) PL2948455T3 (OSRAM)
PT (1) PT2948455T (OSRAM)
RS (1) RS56501B1 (OSRAM)
SG (1) SG11201508005XA (OSRAM)
SI (1) SI2948455T1 (OSRAM)
SM (1) SMT201700526T1 (OSRAM)
WO (1) WO2014154895A1 (OSRAM)
ZA (1) ZA201506234B (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2552920T1 (sl) 2010-04-02 2017-07-31 Ogeda Sa Nove nk-3 receptor selektivne antagonist spojine, farmacevtski sestavki in postopki za uporabo pri nk-3 receptor posredovanih motnjah
CN105175421B (zh) 2011-10-03 2018-07-13 欧歌达有限公司 用于合成选择性nk-3受体拮抗剂的中间体化合物及其用途
US10183948B2 (en) 2013-03-29 2019-01-22 Ogeda Sa N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
JP6316932B2 (ja) * 2013-03-29 2018-04-25 オゲダ エス．エー． 選択的ＮＫ−３受容体拮抗薬としての新規なＮ−アシル−（３位置換）−（８位置換）−５，６−ジヒドロ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン、医薬組成物、ＮＫ−３受容体媒介性障害における使用方法
ES2711143T3 (es) * 2013-03-29 2019-04-30 Ogeda Sa N-acil-(3-sustituido)-5,6,7,8-tetrahidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor de NK-3, composición farmacéutica, métodos para su uso en los trastornos mediados por el receptor de NK-3
ES2721018T3 (es) 2013-03-29 2019-07-26 Ogeda S A N-Acil-(3-sustituido)-(8-metil)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor NK-3, composición farmacéutica, métodos para su uso en trastornos mediados por el receptor de NK-3
PT3197876T (pt) 2014-09-25 2019-02-21 Ogeda Sa Nova síntese quiral de n-acyl-(3-substituído)-(8-substituído)-5,6-di-hidro-[1,2,4]triazolo[4,3-a]pirazinas
KR20170124566A (ko) * 2015-03-16 2017-11-10 오게다 에스.에이. 체지방 과다의 치료적 또는 미용적 치료를 위한 nk-3 수용체 길항제
KR102122470B1 (ko) 2016-12-08 2020-06-12 주식회사 엘지화학 변성제 및 이로부터 유래된 작용기를 포함하는 변성 공액디엔계 중합체
EP3428168A1 (en) * 2017-07-12 2019-01-16 Ogeda Sa Deuterated fezolinetant
JP2021014404A (ja) * 2017-10-13 2021-02-12 アステラス製薬株式会社 トリアゾロピラジン誘導体の塩及び結晶
IL276959B2 (en) 2018-03-14 2024-07-01 Kandy Therapeutics Ltd Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
JP2020050814A (ja) * 2018-09-28 2020-04-02 住友ベークライト株式会社 フェノール変性リグニン樹脂を含む樹脂材料、それを用いたフェノール変性リグニン樹脂組成物および構造体
CA3123757A1 (en) 2018-12-21 2020-06-25 Ogeda Sa Synthesis of 3-methyl-1,2,4-thiadiazole-5-carbohydrazide or of the methyl-d3 deuterated form thereof
CN112272670B (zh) * 2019-04-16 2023-12-12 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
CN113527307B (zh) * 2020-04-20 2024-10-11 上海翰森生物医药科技有限公司 含三唑基的并环类衍生物抑制剂、其制备方法和应用
CN113549074A (zh) * 2020-04-26 2021-10-26 上海翰森生物医药科技有限公司 含三唑基的并环类衍生物抑制剂、其制备方法和应用
JP2023537244A (ja) * 2020-07-30 2023-08-31 上▲海▼翰森生物医▲薬▼科技有限公司 窒素含有縮合環誘導体阻害剤、その調製方法、及びその使用
WO2022031773A1 (en) 2020-08-04 2022-02-10 Teva Pharmaceuticals International Gmbh Solid state forms of fezolinetant and salts thereof
CN115260180B (zh) * 2021-04-30 2024-05-28 长春金赛药业有限责任公司 含三氮唑稠环类衍生物、药物组合物及其制备方法和应用
CN115990164A (zh) * 2021-10-18 2023-04-21 武汉大学 速激肽受体3抑制剂的用途
JP2025504276A (ja) * 2022-01-24 2025-02-12 上▲海▼翰森生物医▲薬▼科技有限公司 窒素含有縮合環系誘導体阻害剤の酸性塩又は結晶形及びその製造方法並びに応用
TW202428579A (zh) * 2022-10-19 2024-07-16 大陸商長春金賽藥業有限責任公司 Ｎｋ３ｒ拮抗劑的晶型及其製備方法和用途
WO2024188143A1 (zh) * 2023-03-10 2024-09-19 山东绿叶制药有限公司 Nk-3受体拮抗剂化合物、药物组合物、其制备方法和应用
WO2025009476A1 (ja) * 2023-07-03 2025-01-09 Ａｇｃ株式会社 ３－メチル－１，２，４－チアジアゾール－５－カルボヒドラジドの新規製造方法
WO2025009477A1 (ja) * 2023-07-03 2025-01-09 Ａｇｃ株式会社 ３－メチル－１，２，４－チアジアゾール－５－カルボヒドラジドの新規製造方法
CN117510506A (zh) * 2023-11-08 2024-02-06 北京康立生医药技术开发有限公司 一种非唑奈坦新的制备方法
WO2025153996A2 (en) 2024-01-16 2025-07-24 Assia Chemical Industries Ltd. Processes for the preparation of enantiomerically enriched r-fezolinetant
EP4628491A1 (en) 2024-04-05 2025-10-08 Química Sintética, S.A. Synthesis of intermediates for the preparation of neurokinin-3 receptor antagonists
WO2025214437A1 (zh) * 2024-04-12 2025-10-16 长春金赛药业有限责任公司 咪唑稠环类化合物、药物组合物及其制备方法和应用
CN118290429B (zh) * 2024-06-06 2024-10-11 山东百诺医药股份有限公司 非唑奈坦中间体及非唑奈坦的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE290862T1 (de) 1999-01-25 2005-04-15 Smithkline Beecham Corp Anti-androgene und verfahren zur behandlung von krankheiten
DE60316416T2 (de) 2002-03-25 2008-06-26 Merck & Co., Inc. Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
WO2004103953A1 (de) 2003-05-21 2004-12-02 Bayer Cropscience Aktiengesellschaft Difluormethylbenzanilide und deren verwendung zur bekämpfung bon mikroorganismen, sowie zwischen produkte und deren herstellung
SI1716152T1 (sl) 2004-02-18 2008-12-31 Astrazeneca Ab Kondenzirane heterociklične spojine in njihova uporaba kot antagonisti metabotropnega receptorja za zdravljenje gastrointestinalnih motenj
GB0509405D0 (en) 2005-05-10 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
SE528833C2 (sv) 2005-07-29 2007-02-27 Metso Paper Inc System och metod för att behandla cellulosamassa i samband med utmatning från en satskokare
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
US7943617B2 (en) * 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
JP5654001B2 (ja) * 2009-04-29 2015-01-14 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐ２Ｘ７調節因子としての５，６，７，８−テトラヒドロ［１，２，４］トリアゾロ［４，３−ａ］ピラジン誘導体
GB0907515D0 (en) 2009-04-30 2009-06-10 Glaxo Group Ltd Compounds
SI2552920T1 (sl) * 2010-04-02 2017-07-31 Ogeda Sa Nove nk-3 receptor selektivne antagonist spojine, farmacevtski sestavki in postopki za uporabo pri nk-3 receptor posredovanih motnjah
US10065960B2 (en) 2010-04-02 2018-09-04 Ogeda Sa NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
CN105175421B (zh) 2011-10-03 2018-07-13 欧歌达有限公司 用于合成选择性nk-3受体拮抗剂的中间体化合物及其用途
JP6316932B2 (ja) * 2013-03-29 2018-04-25 オゲダ エス．エー． 選択的ＮＫ−３受容体拮抗薬としての新規なＮ−アシル−（３位置換）−（８位置換）−５，６−ジヒドロ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン、医薬組成物、ＮＫ−３受容体媒介性障害における使用方法
ES2721018T3 (es) 2013-03-29 2019-07-26 Ogeda S A N-Acil-(3-sustituido)-(8-metil)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor NK-3, composición farmacéutica, métodos para su uso en trastornos mediados por el receptor de NK-3
PT3197876T (pt) 2014-09-25 2019-02-21 Ogeda Sa Nova síntese quiral de n-acyl-(3-substituído)-(8-substituído)-5,6-di-hidro-[1,2,4]triazolo[4,3-a]pirazinas

Also Published As

Publication number Publication date
JP2018118988A (ja) 2018-08-02
EP2948455A1 (en) 2015-12-02
CA2907809C (en) 2021-05-04
ZA201506234B (en) 2019-01-30
PT2948455T (pt) 2017-11-15
US10030025B2 (en) 2018-07-24
HUE035870T2 (hu) 2018-05-28
RS56501B1 (sr) 2018-02-28
DK2948455T3 (da) 2017-11-20
KR102218621B1 (ko) 2021-02-22
EP3219715A1 (en) 2017-09-20
CN105229008A (zh) 2016-01-06
US9422299B2 (en) 2016-08-23
NZ712802A (en) 2020-08-28
PL2948455T3 (pl) 2018-01-31
CY2024019I1 (el) 2024-12-13
US20150232471A1 (en) 2015-08-20
MX2015013711A (es) 2016-02-26
AU2014242906A1 (en) 2015-10-22
CY1119576T1 (el) 2018-03-07
JP2016515565A (ja) 2016-05-30
US9987274B2 (en) 2018-06-05
HUS2400012I1 (hu) 2024-06-28
MX370000B (es) 2019-11-28
AU2014242906A2 (en) 2015-11-05
US20160318941A1 (en) 2016-11-03
EA027570B1 (ru) 2017-08-31
KR102364835B1 (ko) 2022-02-17
FR24C1020I1 (fr) 2024-07-19
KR20160007515A (ko) 2016-01-20
ES2646488T3 (es) 2017-12-14
US20170240551A9 (en) 2017-08-24
IL241473A0 (en) 2015-11-30
BR112015024907B1 (pt) 2023-05-09
JP6316932B2 (ja) 2018-04-25
HK1244273A1 (en) 2018-08-03
CN105229008B (zh) 2017-12-15
NO2948455T3 (OSRAM) 2018-02-24
KR20210021406A (ko) 2021-02-25
NL301272I2 (nl) 2024-06-24
HRP20171688T1 (hr) 2017-12-29
BR112015024907A2 (pt) 2017-07-18
EA201591689A1 (ru) 2016-01-29
LT2948455T (lt) 2017-11-27
AU2014242906B2 (en) 2018-07-26
LTPA2024513I1 (OSRAM) 2024-06-10
US20170095472A1 (en) 2017-04-06
EP2948455B1 (en) 2017-09-27
SI2948455T1 (sl) 2017-12-29
SG11201508005XA (en) 2015-10-29
DK2948455T5 (en) 2018-03-19
FIC20240019I1 (fi) 2024-06-06
SMT201700526T1 (it) 2018-01-11
HK1214816A1 (en) 2016-08-05
CA2907809A1 (en) 2014-10-02
LTC2948455I2 (OSRAM) 2025-11-10
WO2014154895A1 (en) 2014-10-02
CY2024019I2 (el) 2024-12-13

Similar Documents

Publication Publication Date Title
IL241473B (en) N-acyl-6, 5-dihydro-[1,2,4]triazolo[-4,3]pyrazines converted at positions 3 and 8 as selective antagonists of the 3-nk receptor, pharmaceutical preparations containing them, and their uses in the treatment and prevention of Dysfunction of the 3– nk receptor
SI2763992T1 (sl) Novi kiralni n-acil-5,6,7,(8-substituirani)-tetrahidro-(1,2,4)triazolo (4,3-a)pirazini kot selektivni nk-3 receptor antagonisti, farmacevtski sestavek, in postopki za uporabo v nk-3 posredovanih motnjah
PL3838274T3 (pl) Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
IL241573B (en) Transformed histories of [2h]imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidine-4[5h]-one, a pharmaceutical preparation containing them and their use as drugs
SI2547679T1 (sl) Derivati 2,3 dihidro-1H-inden-1-il-2,7-diazaspiro(3.6)nonana in njihova uporaba kot antagonisti ali inverzni agonisti grelinskega receptorja
IL241543B (en) Use of converted 2, 3-dihydroimidazo[1, 2-c] quinazolines for the treatment of lymphoid tissue metastasis
PL3371185T3 (pl) Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych
PL3712152T3 (pl) Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych
IL251107B (en) History of [2h]-imidazo-[1,2-a]pyrazolo[3,4-e]pyrimidine-4(5h)-one, pharmaceutical preparations containing them and their use in disorders of the central nervous system.
LT3041843T (lt) Triazol[4,5-d]pirimidino dariniai kaip cb2 receptorių antagonistai
GB201608227D0 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
ZA201606794B (en) 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one derivatives and their use as antibacterial agents
SG11202002767RA (en) 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof
EP3215510A4 (en) Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
GB201604182D0 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
ZA201508613B (en) Pyrazino[1,2-a]indole compounds, their preparation and use in medicaments
PL2850070T3 (pl) Pochodne benzo[1,3]dioksyny i ich zastosowanie jako antagonistów LPAR5
IL229181A (en) Antifungals 5, 6 - Dihydro - 4h - Pyrolo [1, 2a - [4,1] benzo - diazepines and 6h - Pyrolo [2,1 - a] benzodiazepines preserved with heterocyclic history

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed